Provided by Tiger Trade Technology Pte. Ltd.

Monopar Therapeutics

56.41
+0.61001.09%
Volume:118.80K
Turnover:6.68M
Market Cap:376.96M
PE:-18.87
High:57.65
Open:55.35
Low:53.50
Close:55.80
52wk High:105.00
52wk Low:26.06
Shares:6.68M
Float Shares:4.93M
Volume Ratio:2.08
T/O Rate:2.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9895
EPS(LYR):-4.1123
ROE:-26.54%
ROA:-17.99%
PB:2.66
PE(LYR):-13.72

Loading ...

Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade

Stock Track
·
Nov 14, 2025

BTIG Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Nov 14, 2025

Monopar Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 14, 2025

Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate

Benzinga
·
Nov 13, 2025

Monopar Therapeutics reports third quarter net loss of $3.4 million

Reuters
·
Nov 13, 2025

Press Release: Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

Dow Jones
·
Nov 13, 2025

Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data

TIPRANKS
·
Nov 10, 2025

Leerink Partners Initiates Coverage on Monopar Therapeutics With Outperform Rating, $115 Price Target

MT Newswires Live
·
Nov 10, 2025

Piper Sandler Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Nov 10, 2025

Monopar Therapeutics Initiated at Outperform by Leerink Partners

Dow Jones
·
Nov 10, 2025

Monopar Therapeutics Inc : Chardan Capital Markets Raises Target Price to $100 From $85

THOMSON REUTERS
·
Nov 10, 2025

Monopar presents new data, analyses from Phase 2 ALXN1840-WD-204 study

TIPRANKS
·
Nov 10, 2025

Monopar Therapeutics Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline

Reuters
·
Nov 09, 2025

BTIG Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Nov 06, 2025

Cantor Fitzgerald Remains a Buy on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Nov 05, 2025

Monopar Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

Monopar Therapeutics’ Innovative Imaging Agent Study: Market Implications

TIPRANKS
·
Oct 28, 2025

Monopar Announces Abstract Accepted for Oral Presentation at Aasld - the Liver Meeting® 2025

THOMSON REUTERS
·
Oct 15, 2025

Monopar Therapeutics Initiated at Overweight by Barclays

Dow Jones
·
Oct 13, 2025

Monopar Therapeutics initiated with an Overweight at Barclays

TIPRANKS
·
Oct 13, 2025